New pump system for daratumumab shots under the skin
Part of Blood & lymphatic, Cancer, Heart & circulation, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new pump system (FreedomEDGE®) to give daratumumab as a shot under the skin instead of the usual manual injection. It's for people with multiple myeloma or light chain amyloidosis who are already having daratumumab injections once a month.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have multiple myeloma or light chain amyloidosis.
- Your doctor has prescribed daratumumab as a shot under the skin.
- You currently receive your daratumumab shots manually (not with a pump) and are on the monthly injection schedule.
- You agree to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests if people with multiple myeloma can safely give themselves a medication called daratumumab under the skin at home, instead of going to the hospital for every dose. It aims to see if home self-administration is practical and acceptable for patients.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This trial compares a new injectable medicine (CT-P44) to an approved one (Darzalex Faspro), both given with lenalidomide and dexamethasone, for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the new option works just as well.
Hear when a new Multiple Myeloma or Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.